创新药行情持续火热，建议关注 PD-1/L1 双抗及多抗 [Table_Industry] 医药生物行业周报 [Table_ReportTime] 2025 年 7 月 6 日 证券研究报告 行业研究 [Table_ReportType] 行业周报 医药生物 医药生物 投资评级 看好 上次评级 看好 [Table_A 唐爱金 uthor 医药首席分析师 ] 执业编号：S1500523080002 邮 箱：tangaijin@cindasc.com 贺鑫 医药行业分析师 执业编号：S1500524120003 邮 箱：hexin1@cindasc.com 曹佳琳 医药行业分析师 执业编号：S1500523080011 邮 箱：caojialin@cindasc.com 章钟涛 医药行业分析师 执业编号：S1500524030003 邮 箱：zhangzhongtao@cindasc.com 赵丹 医药行业分析师 执业编号：S1500524120002 邮 箱：zhaodan@cindasc.com 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127号金隅大厦 ...

Index Performance - The CSI A500 Index increased by 1.32% this week, closing at 4662.51 points on July 4 [4] - The average daily trading volume for the week was 18341.42 billion yuan, with a week-on-week decrease of 9.22% [4] Top Performing Stocks - The top ten stocks with the highest gains this week included: 1. Tian Shou Pharmaceutical (600521.SH) with a gain of 23.34% 2. Daqian Energy (688303.SH) with a gain of 22.18% 3. Junshi Biosciences (688180.SH) with a gain of 18.93% 4. Lepu Medical (300003.SZ) with a gain of 17.99% 5. Giant Network (002558.SZ) with a gain of 17.42% 6. Tongwei Co., Ltd. (600438.SH) with a gain of 17.32% 7. Hualing Steel (000932.SZ) with a gain of 15.37% 8. Pengding Holdings (002938.SZ) with a gain of 14.57% 9. Shenzhou Taiyue (300002.SZ) with a gain of 13.70% 10. Dongshan Precision (002384.SZ) with a gain of 13.36% [3] Underperforming Stocks - The ten stocks with the largest declines this week included: 1. Hengxuan Technology (688608.SH) with a loss of 33.40% 2. Huazhi Shihua (688120.SH) with a loss of 32.34% 3. Northern Huachuang (002371.SZ) with a loss of 22.87% 4. Weining Health (300253.SZ) with a loss of 8.77% 5. China Eastern Airlines (600115.SH) with a loss of 7.07% 6. Xingyuan Material (300568.SZ) with a loss of 6.99% 7. Cambricon Technologies (688256.SH) with a loss of 6.50% 8. Beiyi Innovation (603986.SH) with a loss of 5.93% 9. Jixiang Airlines (603885.SH) with a loss of 5.84% 10. New Zhou Bang (300037.SZ) with a loss of 5.49% [3] Fund Performance - This week, 38 CSI A500 funds collectively rose, with Pu Yin An Sheng leading at a 1.72% increase [5] - The top three funds by size were Huatai-PB (200.88 billion yuan), Guotai (181.5 billion yuan), and GF Fund (174.22 billion yuan) [5] Market Trends - A new trend has emerged in the Hong Kong stock market where A-share listed technology companies are increasingly pursuing secondary listings in Hong Kong [7] - The secondary listings provide diversified financing channels and enhance international market recognition for the companies [7] - The median discount rate for five companies planning secondary listings in Hong Kong is approximately -17% [7] - The core factors driving asset performance are expected to shift from external to internal influences in the second half of the year [7]

Group 1 - The China Securities Innovation Drug Industry Index (931152) increased by 0.55%, with notable stock performances including Zhenhua Cell (688520) up 16.46%, Rongchang Bio (688331) up 10.65%, and Aosaikang (002755) up 10.00% [1] - The Innovation Drug 50 ETF (159835) has shown a cumulative increase of 33.49% over the past year, indicating significant growth in its market share [1] - The National Healthcare Security Administration and the National Health Commission released measures to support the high-quality development of innovative drugs, marking a pivotal step in the integration of commercial health insurance into the multi-tiered medical security system [1] Group 2 - Multiple policy releases are seen as significant for the development of innovative drugs, with the introduction of a commercial health insurance innovative drug directory expected to expand market opportunities and encourage pharmaceutical companies to enhance R&D efforts [2] - The domestic innovative drug industry is anticipated to reach a turning point by 2025, shifting from capital-driven growth to profit-driven growth, presenting dual opportunities for performance and valuation recovery [2] - The Innovation Drug 50 ETF closely tracks the China Securities Innovation Drug Industry Index, which selects up to 50 representative listed companies involved in innovative drug R&D to reflect the overall performance of the innovative drug sector [2]

Group 1 - The innovative drug ETF (560900) has seen a 1.14% increase as of July 4, 2025, with an active trading volume of 12.11% [1] - The CSI Innovative Drug Industry Index (931152) rose by 0.95%, with notable increases in constituent stocks such as Zhenjiang Cell (688520) up 19.31% and Rongchang Bio (688331) up 10.54% [1] - Over the past week, the innovative drug ETF (560900) has accumulated a 3.92% increase, reaching a six-month high in its latest scale [1] Group 2 - The National Healthcare Security Administration and the National Health Commission have jointly issued measures to support the high-quality development of innovative drugs, establishing a full-chain policy loop from R&D to payment [2] - The new policy includes the establishment of a commercial health insurance directory for innovative drugs, allowing for confidential pricing mechanisms and special policy treatments [2] - Jianghai Securities noted that the 2025 policy measures will further stimulate R&D efforts and accelerate the market entry of innovative drugs, marking a transition to the 2.0 phase of support policies [2] Group 3 - Morgan Asset Management is integrating its "Global Vision Investment Technology" product line to help investors capitalize on quality tech companies amid a new wave of technological advancements driven by AI [2] - Various actively managed funds focus on emerging industry trends, AI opportunities, and sectors like the new energy vehicle supply chain and humanoid robotics [3] - Passive investment options include the Morgan Hang Seng Technology ETF and the Morgan CSI Innovative Drug Industry ETF, providing easy access to tech assets and innovative drug companies in China [3]

Group 1 - The National Medical Products Administration (NMPA) has announced ten measures to support the innovation and development of high-end medical devices, indicating a clear regulatory support for brain-computer interface technology [1][2] - The establishment of China's first brain-computer interface industrial cluster, "Brain Intelligence World," in Shanghai aims to cultivate over five innovative enterprises with core technology and product development capabilities by 2030 [1] - The healthcare ETF Taikang (159760) has seen a rise of 1.01%, while the index it tracks, the National Certificate Public Health and Medical Health Index (980016), increased by 0.83% [1] Group 2 - The NMPA's recent announcement optimizes the entire lifecycle supervision of high-end medical devices, enhancing policies across various dimensions such as review mechanisms and post-market supervision [2] - Key development directions identified include medical robots, high-end medical imaging equipment, and artificial intelligence medical devices, with expectations for supportive policies in the brain-computer interface sector [2] - The healthcare industry is anticipated to experience sustained recovery due to the advancement of equipment renewal policies and increased government bond issuance [2] Group 3 - As of May 30, 2025, the top ten weighted stocks in the National Certificate Public Health and Medical Health Index (980016) account for 52.46% of the index, including companies like Heng Rui Medicine (600276) and WuXi AppTec (603259) [3]

Core Viewpoint - The innovation drug sector is experiencing a resurgence, driven by supportive policies and a favorable investment environment, marking a significant shift from "squeezing out excess" to "promoting innovation" in the pharmaceutical industry [2][3]. Group 1: Market Performance - In the first half of 2025, the pharmaceutical sector showed strong performance, with the CITIC Pharmaceutical Index rising by 8.11%, outperforming major indices like the Shanghai Composite Index (+5.98%) and the ChiNext Index (+4.25%) [3]. - The A-share innovation drug index increased by 21.84%, while the Hong Kong Hang Seng Innovation Drug Index surged by 60.27% during the same period [4]. Group 2: Policy Support and Industry Trends - The recent policy document titled "Several Measures to Support the High-Quality Development of Innovative Drugs" outlines 16 measures to support the entire chain of innovative drug development, indicating a systemic shift in policy support [2][7]. - The domestic pharmaceutical industry has undergone a transformation since the "4+7" procurement policy was implemented in 2018, leading to a fruitful period for innovative drugs in 2025 as the results of this transformation begin to materialize [7]. Group 3: Future Outlook - The innovation drug sector is expected to remain a key investment focus in the third quarter, with core innovative drug assets requiring attention despite potential short-term fluctuations [8]. - The CDMO (Contract Development and Manufacturing Organization) sector is anticipated to see a revenue recovery trend continuing into the second quarter of 2025, as the industry has established an order inflection point [9]. - The CRO (Contract Research Organization) and front-end innovative drug sectors are set to benefit from overseas licensing deals, which will bring incremental revenue expectations from upfront payments [10].

Market Overview - The Shanghai Composite Index rose by 0.18% on July 3, with 24 out of the 28 sectors in the Shenwan classification experiencing gains. The leading sectors were electronics and electrical equipment, with increases of 1.69% and 1.38% respectively. The pharmaceutical and biological sector ranked third in terms of gains [1] - The coal and transportation sectors saw the largest declines, with decreases of 1.16% and 0.28% respectively [1] Fund Flow Analysis - The main funds in the two markets experienced a net outflow of 4.511 billion yuan throughout the day. Nine sectors saw net inflows, with the electronics sector leading at a net inflow of 7.820 billion yuan, followed by the pharmaceutical and biological sector with a net inflow of 1.382 billion yuan [1] - A total of 22 sectors experienced net outflows, with the machinery equipment sector leading at a net outflow of 2.317 billion yuan, followed by the basic chemicals sector with a net outflow of 1.908 billion yuan [1] Pharmaceutical and Biological Sector Performance - The pharmaceutical and biological sector increased by 1.35% with a net inflow of 1.382 billion yuan. Out of 474 stocks in this sector, 388 stocks rose, and 12 stocks hit the daily limit up. Conversely, 83 stocks declined [2] - Among the stocks with net inflows exceeding 100 million yuan, Huahai Pharmaceutical led with a net inflow of 269 million yuan, followed by Changchun High-tech and Zhongsheng Pharmaceutical with net inflows of 266 million yuan and 178 million yuan respectively [2] - The stocks with the largest net outflows included Dongfang Ocean, Changshan Pharmaceutical, and Mindray Medical, with net outflows of 186 million yuan, 155 million yuan, and 121 million yuan respectively [2][3] Top Gainers in Pharmaceutical Sector - The top gainers in the pharmaceutical sector included: - Huahai Pharmaceutical: +10.01%, turnover rate 4.98%, net inflow 268.63 million yuan - Changchun High-tech: +10.00%, turnover rate 4.06%, net inflow 266.41 million yuan - Zhongsheng Pharmaceutical: +6.22%, turnover rate 13.53%, net inflow 177.88 million yuan [2] Top Losers in Pharmaceutical Sector - The top losers in the pharmaceutical sector included: - Dongfang Ocean: -1.29%, turnover rate 25.09%, net outflow -186.29 million yuan - Changshan Pharmaceutical: +0.41%, turnover rate 2.88%, net outflow -154.59 million yuan - Mindray Medical: -2.13%, turnover rate 0.63%, net outflow -120.66 million yuan [3]

Group 1 - The innovative drug concept sector rose by 2.49%, ranking 7th among concept sectors, with 196 stocks increasing in value [1] - Notable gainers included Guoshentang and Shenzhou Cell, both reaching a 20% limit up, while stocks like Jiuzhitang, Weiming Pharmaceutical, and Huahai Pharmaceutical also hit the limit up [1] - The top gainers in the sector included Shanghai Yizhong, Saiseng Pharmaceutical, and Rejing Biomedical, with increases of 10.82%, 10.45%, and 10.38% respectively [1] Group 2 - The innovative drug sector saw a net inflow of 1.887 billion yuan, with 122 stocks receiving net inflows, and 6 stocks exceeding 100 million yuan in net inflow [2] - Huahai Pharmaceutical led the net inflow with 269 million yuan, followed by Changchun Gaoxin, Zhongsheng Pharmaceutical, and Jiuzhitang with net inflows of 266 million yuan, 178 million yuan, and 172 million yuan respectively [2] - The stocks with the highest net inflow ratios included Jiuzhitang, Weiming Pharmaceutical, and Huahai Pharmaceutical, with net inflow ratios of 33.17%, 24.18%, and 17.37% respectively [3] Group 3 - The innovative drug sector's top stocks by trading volume included Huahai Pharmaceutical, Changchun Gaoxin, and Zhongsheng Pharmaceutical, with trading volumes of 26.863 million yuan, 26.640 million yuan, and 17.787 million yuan respectively [3][4] - Other notable stocks included Guoshentang, which had a trading volume of 13.697 million yuan, and Weiming Pharmaceutical with 8.946 million yuan [4] - The sector's performance was characterized by significant trading activity, with many stocks experiencing high turnover rates [4]

Group 1 - The A-share market experienced a volatile upward trend on July 3, with the Shanghai Composite Index closing at 3461.15 points, an increase of 0.18%, marking a new high for the year [1] - The ChiNext Index showed stronger performance, closing with a gain of 1.90% [1] - The A500 ETF by Jiashi (159351) closed up 0.71%, reaching its highest closing price since March 21 of this year, with a total trading volume of 3.178 billion yuan, ranking second in the market for similar products [1] Group 2 - The A500 ETF tracks the CSI A500 Index, which consists of 500 stocks with large market capitalization and good liquidity, providing a balanced industry distribution and a focus on large and mid-cap styles [2] - The fund is seen as a tool for investors to access representative A-share companies, with a significant proportion of new productive forces among its components [2]

Core Viewpoint - The 中证A500 index represents a balanced selection of leading companies across various industries, reflecting the overall performance of the most representative listed companies in China, with a focus on both traditional and emerging sectors [1][2]. Group 1: Market Performance - As of July 3, 2025, the 中证A500 index rose by 0.60%, with notable increases in constituent stocks such as 蓝思科技 (up 12.14%) and 东山精密 (up 9.29%) [1]. - The 中证A500ETF leading fund (563800) also saw a rise of 0.62%, with a trading volume of 8.54 billion yuan and a turnover rate of 4.9% [1]. Group 2: Industry Insights - The 中证A500 index includes leading companies from various industries, indicating a competitive and stable force within the Chinese economic system, especially as market concentration is expected to increase due to accelerated mergers and acquisitions [2]. - The index is designed to balance traditional and emerging industries, with a significant weight on sectors like pharmaceuticals, new energy, and computing, aiming for a balance between value and growth [1][2]. Group 3: Future Outlook - Analysts predict that the A-share market may exhibit a trend of upward fluctuations in the second half of 2025, supported by the expansion of equity public funds and stable capital inflows [2]. - The 中证A500 index is expected to benefit from improvements in fundamentals, policy catalysts, and institutional optimization, leading to a potential recovery in profitability [2].